Biotech

All Articles

BMS ditches TIGIT, leaving $200M bank on Agenus bispecific

.Bristol Myers Squibb is actually axing an additional large bet coming from the Caforio time, cancel...

Nuvation stops BET inhibitor after looking at phase 1 data

.After looking at phase 1 record, Nuvation Biography has actually determined to halt deal with its o...

' Scientific intuitiveness' led FDA specialists to support Zevra's uncommon health condition med

.Zevra Therapeutics' uncommon illness medicine seems to be to be on the path to approval this loss a...

Pfizer takes $230M struck after axing stopped working DMD gene therapy

.Pfizer's phase 3 Duchenne muscular dystrophy (DMD) gene therapy failing has gone a $230 million gap...

AC Immune views 'site' potential in Alzheimer's medication records

.After greater than 20 years of deal with neurodegenerative diseases, Swiss biotech air conditioner ...

GSK falls ph. 2 HPV vaccination over absence of best-in-class possible

.GSK has junked a phase 2 individual papillomavirus (HPV) vaccine coming from its pipe after decidin...

OS Treatments refiles $6M IPO to fund HER2 medicine, preclinical ADCs

.Operating system Therapies will definitely list on the NYSE American sell substitution this morning...

ALX's fizzling CD47 action rate sends out stock spiraling down

.ALX Oncology's stage 2 stomach cancer action price has actually compromised. After finding its own ...

Ionis axes eye disease from aim ats of Roche-partnered possibility after records let down

.Yet Another of Ionis Pharmaceuticals' vital midphase readouts has actually disappointed requirement...

Biogen's chief executive officer stated no dangerous sell 2023. He's ready to become strong

.While Biogen's pharma peers are actually looking for late-stage possessions with little danger, CEO...